Sfoglia per RIVISTA
AMERICAN JOURNAL OF HEMATOLOGY
Collezione AOU Alessandria

  

Items : 10

Continuous venetoclax in treatment-naive TP53 disrupted patients with chronic lymphocytic leukemia: A chronic lymphocytic leukemia campus study. in American journal of hematology / Am J Hematol. 2023 Sep;98(9):E237-E240. doi: 10.1002/ajh.27009. Epub 2023 Jun 29.

2023
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria

Trentin L; Cuneo A; Foà R; Ghia P; Coscia M; Laurenti L; Molica S; Zatta I; Cavarretta CA; Angotzi F; Cellini A; Ruocco V; Rigolin GM; Sportoletti P; Trimarco V; Murru R; Marchetti M; Pietrasanta D; Cibien F; Vitale C; Sanna A; Derenzini E; Proietti G; Ferrarini I; Reda G; Mauro FR; Scarfò L; Gentile M; Farina L; et alii...

Efficacy of front-line ibrutinib versus fludarabine, cyclophosphamide, and rituximab in patients with chronic lymphocytic leukemia: A retrospective multicenter "Real-World" study. in American journal of hematology / Am J Hematol. 2023 Feb;98(2):E24-E27. doi: 10.1002/ajh.26779. Epub 2022 Nov 25.

2023
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Levi S; Trentin L; Foà R; Cuneo A; Herishanu Y; Gentile M; Perry C; Gattei V; Gaidano G; Rossi D; Neri A; Olivieri J; Bomben R; Zucchetto A; Visentin A; Loseto G; Pietrasanta D; Chiarenza A; Braester A; Murru R; Aviv A; Varettoni M; Coscia M; Tadmor T; Shvidel L; Sportoletti P; Laurenti L; Reda G; Ruchlemer R; et alii...

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: A study by ERIC, the European research initiative on CLL. in American journal of hematology / Am J Hematol. 2023 Dec;98(12):1856-1868. doi: 10.1002/ajh.27093. Epub 2023 Sep 29.

2023
AOU Novara
AOU Alessandria
AOU Città della Salute di Torino

Montserrat E; Stamatopoulos K; Trentin L; Stavroyianni N; Cuneo A; Rambaldi A; Coscia M; Ghia P; Segundo LYS; Yassin M; Pocali B; Vandenberghe E; Iyengar S; Wróbel T; Wasik-Szczepanek E; van Kampen R; van Gelder M; Te Raa D; Tonino SH; Van Der Spek E; Reda G; Saghumyan G; Shrestha A; Mirás F; Del Poeta G; Gutwein O; Karlsson LK; Milosevic I; Tadmor T; et alii...

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts. in American journal of hematology / Am J Hematol. 2023 Aug;98(8):E204-E208. doi: 10.1002/ajh.26960. Epub 2023 May 24.

2023
ASL Città di Torino
ASL Torino 4
AO Cuneo
ASL Biella
AO Ordine Mauriziano
AOU Città della Salute di Torino
AOU Novara
AOU Alessandria

Della Porta MG; Naldi I; Santini V; Turrini M; Giordano L; Finelli C; Pasini P; Tosi P; Tanasi I; Selleri C; Frigeni M; Sancetta R; Norata M; Marchetti M; Grimaldi D; Fianchi L; Galimberti S; Ferrara F; Di Veroli A; Di Bona E; Occhini U; Rivoli G; Bono R; Calvisi A; Castelli A; Nicolino B; Leuzzi L; Molteni A; Guarini A; et alii...

Continuous treatment with Ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia: A real-life campus CLL study. in American journal of hematology / Am J Hematol. 2022 Mar 1;97(3):E95-E99. doi: 10.1002/ajh.26437. Epub 2021 Dec 21.

2022
AO Cuneo
ASL Cuneo 1
AOU Città della Salute di Torino
AOU Alessandria

Cuneo A; Trentin L; Foà R; Molica S; Laurenti L; Pravato S; Marchetti M; Murru R; Gentile M; Rigolin GM; Quaglia FM; Coscia M; Piazza F; Reda G; Fresa A; Ciolli S; Scarfò L; Sportoletti P; Pietrasanta D; Vitale C; Mauro FR; Cibien F; Visentin A;

Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19. in American journal of hematology / Am J Hematol. 2022 Dec;97(12):E470-E473. doi: 10.1002/ajh.26732. Epub 2022 Sep 27.

2022
AOU Città della Salute di Torino
AOU Novara
AOU Alessandria

Vannucchi AM; Rambaldi A; Curto-Garcia N; Cavalca F; Bellini M; Betti S; Borsani O; de Na??cz AK; Cattaneo D; Bucelli C; Cichocka E; Koschmieder S; Lopez Abadia E; Kusec R; Xicoy Cirici B; Angona A; Navas Elorza B; Sagues Serrano M; Carreno-Tarragona G; Osorio S; Carli G; Hernandez-Boluda JC; Garcia-Gutierrez V; Marin Sanchez A; Magro Mazo E; Griesshammer M; Quiroz Cervantes K; Bolaños Calderón E; Patriarca A; et alii...

Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study. in American journal of hematology / Am J Hematol. 2021 May 1;96(5):E168-E171. doi: 10.1002/ajh.26127. Epub 2021 Feb 24.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Foà R; Ferrarini M; Polliack A; Gaidano G; Trentin L; Cuneo A; Fronza G; Cutrona G; Rossi D; Di Raimondo F; Neri A; Bomben R; Biagi A; Del Giudice I; Angeletti I; Galimberti S; Rago A; Caracciolo D; Cassin R; D'Arrigo G; Mendicino F; Botta C; Martino EA; Vigna E; Zucchetto A; Rossi FM; Scortechini I; et alii...

Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E269-E272. doi: 10.1002/ajh.26201. Epub 2021 May 3.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

D Arrigo G; Murru R; Gentile M; Gattei V; Polliack A; Trentin L; Gaidano G; Di Raimondo F; Cuneo A; Cutrona G; Rossi D; Menichini P; Olivieri J; Fronza G; Monti P; Del Giudice I; Bomben R; Neri A; Angeletti I; Biagi A; Rago A; Martino EA; Cassin R; Galimberti S; Foà R; Ferrarini M; Scortechini I; Rossi FM; Zucchetto A; et alii...

TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases. in American journal of hematology / Am J Hematol. 2021 Aug 1;96(8):E306-E310. doi: 10.1002/ajh.26235. Epub 2021 May 25.

2021
AO Cuneo
AOU Città della Salute di Torino
AOU Alessandria
AOU Novara

Gentile M; Gattei V; Ferrarini M; Foà R; Polliack A; Trentin L; Cuneo A; Gaidano G; Di Raimondo F; Rossi D; Olivieri J; Jaksic O; Bomben R; Neri A; Fronza G; Rago A; Angeletti I; Cutrona G; Del Giudice I; Biagi A; Galimberti S; D'Arrigo G; Al-Janazreh H; Martino EA; Vigna E; Tripepi G; Zucchetto A; Rossi FM; Recchia AG; et alii...

The use of ATG abrogates the antileukemic effect of cytomegalovirus reactivation in patients with acute myeloid leukemia receiving grafts from unrelated donors. in American journal of hematology / Am J Hematol. 2015 Jun;90(6):E117-21. doi: 10.1002/ajh.23998. Epub 2015 Apr 1.

2015
AOU Città della Salute di Torino
AOU Alessandria

Cavallo R; Costa C; Maffini E; Giaccone L; Audisio E; Dellacasa C; Zallio F; Pini M; Passera R; Busca A; Bruno B;